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Extracellular vesicles (EVs) are relevant means for transferring signals across cells and
facilitate propagation of oncogenic stimuli promoting disease evolution and metastatic spread
in cancer patients. Here, we investigated the release of miR-424 in circulating small EVs or
exosomes from prostate cancer patients and assessed the functional implications in multiple
experimental models. We found higher frequency of circulating miR-424 positive EVs in
patients with metastatic prostate cancer compared to patients with primary tumors and BPH.
Release of miR-424 in small EVs was enhanced in cell lines (LNCaPabl), transgenic mice (Pb-
Cre4;Ptenflox/flox;Rosa26ERG/ERG) and patient-derived xenograft (PDX) models of aggressive
disease. EVs containing miR-424 promoted stem-like traits and tumor-initiating properties in
normal prostate epithelial cells while enhanced tumorigenesis in transformed prostate epi-
thelial cells. Intravenous administration of miR-424 positive EVs to mice, mimicking blood
circulation, promoted miR-424 transfer and tumor growth in xenograft models. Circulating
miR-424 positive EVs from patients with aggressive primary and metastatic tumors induced
stem-like features when supplemented to prostate epithelial cells. This study establishes that
EVs-mediated transfer of miR-424 across heterogeneous cell populations is an important
mechanism of tumor self-sustenance, disease recurrence and progression. These findings
might indicate novel approaches for the management and therapy of prostate cancer.
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Prostate cancer is the most frequent cause of cancer-relatedmortality in men1. Aggressive forms of prostate cancersrapidly progress to metastatic, hormone-refractory, and
lethal disease. Paracrine propagation of oncogenic signals by
horizontal transfer across cell types is a dynamic process that can
promote cell plasticity, metastatic spread and treatment resis-
tance2–4. However, the underlying mechanisms are still elusive. In
this context, small extracellular vesicles (EVs) or exosomes of
30–150 nm in diameter can serve as efficient means for trans-
ferring intracellular content, allowing cell-to-cell communication
within the tumor microenvironment and at distant sites2,3. Small
EVs contain nucleic acids, lipids, and proteins2. MicroRNAs
(miRNAs) are frequently packaged into exosomes and are
secreted in the extracellular environment5–7. Exosome-
encapsulated miRNAs are extremely stable and are found in all
body fluids, including blood6–9. Therefore, miRNAs loaded in
exosomes released by normal and cancer cells can influence the
behavior of other cell types by transferring their tumor-
promoting or tumor-suppressing capability2,10.
We have shown that the transcription factor ESE3/EHF is
frequently downregulated in prostate cancer and its loss induces
cell plasticity and acquisition of mesenchymal, stem-like and
tumor-initiating properties11–13. We found that loss of ESE3/EHF
led to increased expression of miR-424 that acted as a potent
oncogenic effector activating a complex program involving COP1
repression and induction of multiple oncogenic transcription
factors, including STAT3, c-JUN, and ETV114. Interestingly,
transient expression of miR-424 in immortalized normal prostate
epithelial cells was sufficient to promote stem-like and tumor-
initiating features, suggesting that transfer of miR-424 across
distinct cell types could modify persistently the recipient cells and
amplify the extent of miR-424 oncogenic signaling14.
In this study, we investigated whether miR-424 was secreted in
small EVs or exosomes released by prostate tumors and whether
it could act in paracrine and endocrine manner in order to
promote tumorigenic phenotypes in low tumorigenic cells at both
proximal and distal sites. We detected EVs carrying miR-424 in
plasma of prostate cancer patients and examined the functional
implications of EVs-released miR-424 using multiple in vitro and
in vivo experimental models. We show that miR-424-loaded EVs
from cell lines, mouse models, patient-derived xenografts (PDX)
and patient samples promote stem-like features and tumorigenic
capability in recipient cells. Therefore, EVs-mediated release of
miR-424 can serve as an efficient means for transferring onco-
genic signals across cells in the surrounding microenvironment
and at distal metastatic sites promoting disease recurrence and
progression.
Results
Aggressive prostate cancers release miR-424 containing EVs.
We hypothesized that miR-424-positive tumors could release
miRNA-loaded exosomes in the extracellular environment and
blood circulation. To test this, we collected blood and isolated
small EVs from plasma of patients (n= 64) with benign prostatic
hyperplasia (BPH) (n= 6), primary (n= 25), metastatic
castration-sensitive (mCSPC) (n= 16), and metastatic castration-
resistant (mCRPC) (n= 17) prostate cancers (Fig. 1A). Both
morphology and size (<100 nm) were consistent with the isola-
tion of small EVs as determined by transmission electron
microscopy (TEM) and nanoparticle-tracking analysis (NTA)
(Fig. 1B and C), in accordance with the standard MISEV guide-
lines15. MACS-PLEX analysis showed expression of the EVs-
marker proteins CD9, CD63, CD81 in representative patient
samples from all groups (Fig. 1D). Immunoblotting confirmed
the presence of CD81 and the absence of contaminating cellular
proteins such as GRP94 and calnexin (Supplementary Figs. 1 and
9). We measured the level of miR-424 in plasma EVs from BPH
and tumor samples by RT-qPCR. miR-424 was not detected
(Ct ≥ 40) in BPH samples, while the percentage of positivity
increased from primary tumors to mCSPCs and mCRPCs
(Fig. 1E). Notably, mCRPC-derived EVs had higher levels of miR-
424 compared to normal and primary tumors, while the differ-
ence was not statistically significant for mCSPCs (Fig. 1F). These
findings were in line with an impact of miR-424 in progression to
metastatic and hormone-refractory prostate cancer. Importantly,
our present finding implied that EVs-mediated release of miR-
424 in the extracellular environment and blood circulation could
expand the range and amplify the oncogenic effects of this
miRNA in prostate cancer patients.
miR-424-loaded EVs drive stem-like and tumorigenic traits in
recipient cells. To investigate the function of secreted miR-424,
we collected conditioned medium (CM) from prostate donor cells
engineered to stably express miR-424 and assessed the effects in
miR-424-negative recipient cells (Fig. 2A). Both RWPE-1 miR-
424 and LNCaP miR-424 donor cells had significantly higher
levels of miR-424 than corresponding control cells (Fig. 2B).
Supplementation of CM from donor cells resulted in transfer of
miR-424 to the recipient RWPE-1 and LNCaP cells (Fig. 2C). The
same was observed when RWPE-1 cells transiently transfected
with premiR-424 were used as donor cells. Donor RWPE-1 cells
exhibited a high level of mature miR-424 compared to control
cells (Fig. 2D) and the CM from these cells (CM-miR-424)
increased miR-424 level in recipient cells (Fig. 2E). Notably,
transfer of CM containing miR-424 to recipient cells significantly
enhanced tumor-sphere formation (Fig. 2F–H), clonogenic cap-
ability (Fig. 2G) and cell migration (Fig. 2I) compared to control
CM.
Next, we verified whether this involved the release of miR-424-
loaded EVs from donor cells and their transfer to recipient cells
(Fig. 3A). Small EVs were isolated from CM of both control and
miR-424 expressing cells. The isolated EVs exhibited the expected
morphology and size (<150 nm) as revealed by TEM and NTA
(Fig. 3B and Supplementary Fig. 2A). MACS-PLEX (Fig. 3C) and
immunoblotting (Supplementary Figs. 2B and 10 and 11) also
showed the presence of canonical EVs markers. Importantly,
miR-424-expressing cells secreted EVs with high miR-424
content (Fig. 3D). Following supplementation, fluorescently
labeled EVs from both control and miR-424-expressing cells
were taken up by recipient cells (Fig. 3E) and the miR-424-loaded
EVs transferred efficiently the miRNA into recipient cells
(Fig. 3F). Importantly, miR-424 was internalized within EVs,
protected by the EVs phospholipid membrane from degradation,
as shown by its resistance to RNase treatment (Supplementary
Fig. 3). Supplementation of EVs from miR-424 positive (EVs-
424) to RWPE-1 and LNCaP cells significantly increased tumor-
sphere formation compared to EVs from negative control (EVs-
CTRL) cells (Fig. 3G), reproducing the effects of CM.
To confirm that miR-424-loaded EVs promoted tumor-sphere
formation, we differentially labeled miR-424 positive (EVs-424)
and negative (EVs-CTRL) EVs with either red (PKH26) or green
(PKH67) fluorescent dyes. Labeled EVs were mixed in equal
amounts and supplemented to recipient cells. Retention of the
labeled EVs in the progeny of tumor-sphere cells would indicate
the source of the EVs that they had received. Immediately after
supplementation, recipient cells showed both red and green
fluorescence, indicating equal distribution and uniform intake of
the stained EVs (Fig. 3H). At the end of the assay, we found a
significant enrichment of red-stained tumor-spheres (Fig. 3I),
consistent with the notion that miR-424-loaded EVs had greater
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ability to promote tumor-sphere formation. To determine
whether the acquisition of stem-like traits by miR-424 containing
EVs led to increased tumorigenesis, RWPE-1 cells were incubated
with EVs-CTRL or EVs-424 in vitro and then were implanted
subcutaneously in mice. EVs-424-treated RWPE-1 cells formed
larger tumors (≥100mm3) compared to EVs-CTRL treated and
untreated RWPE-1 cells (Fig. 3J). Consistently, LNCaP cells
supplemented with EVs-424 generated bigger tumors than EVs-
CTRL-treated LNCaP cells (Fig. 3K). Thus, supplementation of
miR-424-containing EVs promoted tumor-forming capability in
immortalized prostate epithelial cells RWPE-1 and enhanced
in vivo tumorigenic potential of prostate cancer cells LNCaP.
Secretion of miR-424 in EVs is enhanced in the transition from
indolent to aggressive phenotype in experimental prostate
cancer models. To support the association between miR-424
upregulation and acquisition of aggressive traits, we examined the
expression of miR-424 and release into EVs in LNCaPabl cells, a
CRPC cell model derived from LNCaP cells by continuous
growth in androgen-depleted medium16 (Fig. 4A). First, we found
significantly higher expression of miR-424 in LNCaPabl compared
to parental cells, in line with a link between miR-424 upregulation
and progression to CRPC (Fig. 4B). Furthermore, LNCaPabl cells
secrete EVs significantly enriched of miR-424 compared to par-
ental cells (Fig. 4C). Characterization of EVs from LNCaPabl cells
by NTA, MACS-PLEX, and immunoblot, indicated that were
similar in size to those from parental LNCaP cells and presented
similar EVs-specific markers (Fig. 4D and Supplementary
Figs. 4A, B and 12). Thus, elevation of miR-424 occurred during
the transition to the CRPC phenotype and was associated with a
concomitant enrichment of miR-424 in EVs secreted from
LNCaPabl cells.
Next, we supplemented RWPE-1 recipient cells with EVs from
parental and LNCaPabl cells. We found similar uptake of EVs in
recipient cells using parental and LNCaPabl-derived EVs (Fig. 4E).
However, LNCaPabl-derived EVs increased miR-424 level (Fig. 4F)
and concomitantly enhanced tumor-sphere formation (Fig. 4G),
and cell migration (Fig. 4H) in recipient cells compared to EVs
from parental LNCaP cells. These data further supported the
potential impact of miR-424 in the prostate cancer evolution.
Interestingly, pretreatment of recipient cells with Bafilomycin A1,






















































































































































SIZE (nm) SIZE (nm) SIZE (nm) SIZE (nm)
BPH vs mCRPC p-value: 0.0022 
PRIMARY vs mCRPC p-value: 0.0009 
BPH vs mCRPC p-value: 0.01 






RATIO: 1’067’228.66 812’446.80 134’298.56 86’351.93
PROTEIN:
RATIO:
2476.85 14083.56 4093.75 4904.16
13’277.89 153’420.68 179’541.98 76’669.60
Fig. 1 Metastatic prostate cancers release miR-424 containing extracellular vesicles in patient plasma. A Scheme of the experimental plan for isolation
and characterization of EVs from patient plasma. B and C Representative images of transmission electron microscopy (TEM) and nanoparticle tracking
analysis (NTA) of patient-derived EVs. EVs protein concentrations and ratios between NTA counts vs. protein are reported. D Expression of EVs surface
markers in patient-derived EVs determined by MACSPlex analysis. E Percentage of miR-424-positive EVs isolated from plasma of patients with BPH and
prostate cancer. F miR-424 expression levels (Ct values) in EVs from patient plasma. Comparisons with significant p-value (<0.05) are indicated and only
significant p-values are reported. n= 6 BPH, n= 25 PRIMARY, n= 16 mCSPC, n= 17 mCRPC. In NTA panels the unit of measurements were particles/mL.
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Fig. 2 Paracrine impact of secreted miR-424. A Experimental design for phenotypic analysis. B miR-424 levels in RWPE-1 and LNCaP donor cells stably
expressing miR-424 or control plasmid. C miR-424 levels in recipient cells (RWPE-1) and (LNCaP) following the addition of conditioned medium (CM)
from donor cells with (CM-424) or without (CM-CTRL) stable expression of miR-424. D miR-424 level in RWPE-1 cells transfected with pre-miR-424
(424) or negative control pre-miRNA (CTRL). E miR-424 transfer in recipient RWPE-1 cells following incubation with CM from control or pre-miR-424
transfected RWPE-1 cells. F Tumor-sphere forming efficiency (SFE) of RWPE-1 recipient cells incubated with CM from RWPE-1 and LNCaP donor cells with
(CM-424) or without (CM-CTRL) miR-424 expression. G and H Colony (G) and tumor-sphere formation (H) after supplementation of CM from control or
pre-miR-424 transfected RWPE-1 cells. Representative images are shown at bottom of panels F and G. I Cell migration capacity measured in wound-
healing assay of RWPE-1 cells after supplementation of CM from control and pre-miR-424 transfected RWPE-1 cells. Right: quantification of wound width
closure percentage. *p≤ 0.05, **p≤ 0.01 by two-tailed Student’s t-test.
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the increase in tumor-sphere formation following supplementa-
tion with exosome from LNCaPabl cells, indicating that the EVs
cargo delivery occurred through the endosomal pathway
(Supplementary Fig. 5). To better understand the role of miR-
424 as a key mediator of the phenotypes induced by EVs secreted
from LNCaPabl cells, we ablated miR-424 in LNCaPabl cells,
isolated EVs and supplemented them to recipient cells to evaluate
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Fig. 3 EVs-secreted miR-424 drives the acquisition of stem cell traits and in vivo tumorigenesis. A Schematic of EVs isolation and functional
characterization. B Representative image of transmission electron microscopy (TEM) of cell line-derived EVs. C EV-surface markers in cell line-derived EVs
by MACSPlex analysis. D miR-424 levels in EVs derived from RWPE-1 and LNCaP cells with (EVs-424) and without (EVs-CTRL) stable expression of miR-
424. E Visualization of recipient cells incubated with fluorescently labeled EVs (PKH26, red) from RWPE-1 and LNCaP donor cells by confocal microscopy.
Nuclei were stained with Hoechst (blue). F Level of miR-424 in RWPE-1 (upper) and LNCaP (lower) recipient cells incubated with EVs-CTRL or EVs-424. G
Tumor-sphere formation by RWPE-1 (upper) and LNCaP (lower) cells supplemented with EVs-CTRL or EVs-424. H Confocal microscopy images of RWPE-
1 recipient cells incubated for 24 h with EVs-CTRL or EVs-424 labeled with PKH67 (green) or PKH26 (red) fluorescent dyes. I Confocal microscopy images
of tumor-spheres formed by RWPE-1 cells incubated with fluorescently labeled EVs as above. Right: quantification of fluorescently labeled tumor-spheres. J
Growth of subcutaneous xenografts of RWPE-1 cells supplemented in vitro with EVs-CTRL and EVs-424 derived from stably expressing donor LNCaP cells.
n= 4/group. K Tumor growth of LNCaP cells supplemented in vitro with EVs-CTRL and EVs-424 derived from stably expressing LNCaP donor cells. n= 4/
group. Right panels, H&E and IHC staining for Ki67 in xenograft explants.*p≤ 0.05, **p≤ 0.01 by two-tailed Student’s t-test.
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nucleic acid (LNA)-424, a specific miR-424 antagonist14,
significantly reduced miR-424 level in LNCaPabl cells (Fig. 4J).
Consequently, EVs supplementation to recipient cells resulted in
lower level of miR-424 intake (Fig. 4K), and reduced tumor-
sphere formation compared to EVs from LNA-control transfected
cells (Fig. 4L). These data demonstrated that EVs from LNCaPabl
cells promoted stem-like features in recipient cells by releasing
miR-424 and support a role of miR-424 in disease progression.
Secretion of miR-424 in EVs from aggressive mouse models
and human prostate tumors. To examine the release of miR-424
into small EVs from prostate tumors, we established sub-
cutaneous xenografts of control and miR-424-positive LNCaP
cells in mice (Fig. 5A). As expected, tumors of miR-424 expres-
sing LNCaP cells grew larger than control tumors (Fig. 5B) and
retained high expression of miR-424 (Fig. 5C). Next, EVs were
isolated from tumor explants according to a published protocol17.
Small EVs isolated from miR-424-positive tumors contained high
amounts of miR-424 compared to control xenografts (Fig. 5D).
Furthermore, tumor-derived EVs were fully functional and
promoted tumor-sphere formation (Fig. 5E) and cell migration
(Fig. 5F), when supplemented to miR-424-negative recipient cells.
Thus, tumor xenografts in mice secrete functional EVs that
transfer miR-424 and induce malignant phenotypes in recipient
cells.
To gain further evidence of tumor release of miR-424-loaded
EVs and the association with aggressive phenotype, we used a
genetically engineered mouse model (GEMM) of aggressive
prostate cancer18 (Fig. 5G). Pb-Cre4;Ptenflox/flox;Rosa26ERG/ERG
(ERG/PTEN) mice combine conditional prostate-specific PTEN
deletion and ERG overexpression and develop invasive prostate
adenocarcinomas18. Notably, we found that prostate tumors of
ERG/PTEN mice express higher level of miR-322, the murine
orthologous of miR-424, than prostatic tissue from wild type
(WT) mice (Fig. 5H). Consistently, small EVs from murine ERG/
PTEN tumors had higher content of miR-322 (Fig. 5I). EVs
isolated from ERG/PTEN and WT mice were equally taken up by
RWPE-1 cells (Fig. 5J). Notably, RWPE-1 cells receiving ERG/
PTEN-derived EVs had significantly higher level of miR-322

































































































































































































Fig. 4 EVs secretion of miR-424 is enhanced during the transition from indolent to aggressive phenotype in experimental models. A Isolation and
assessment of EVs in LNCaP and LNCaPabl cells. B miR-424 expression in LNCaP and LNCaPabl cells. CmiR-424 levels in EVs derived from parental LNCaP
and LNCaPabl cells. D Surface markers in EVs from LNCaP (EVs-PAR) and LNCaPabl (EVs-ABL) cells. E Confocal images of RWPE-1 recipient cells
incubated for 48 h with PKH26-labeled EVs (red) from LNCaP and LNCaPabl cells. Nuclei were stained with Hoechst (blue). F Level of miR-424 in recipient
RWPE-1 after supplementation of EVs from parental (EVs-PAR) or LNCaPabl (EVs-ABL) cells. G Tumor-sphere formation by RWPE-1 cells supplemented
with EVs from parental (EVs-PAR) or LNCaPabl (EVs-ABL) cells. H Cell migration by wound healing assay in recipient RWPE-1 cells incubated with EVs
from parental (EVs-PAR) or LNCaPabl (EVs-ABL) cells. I Schematic of the experimental blockade of miR-424 transfer through EVs in LNCaPabl cells. J Level
of miR-424 in LNCaPabl donor cells transfected with LNA-CTRL or LNA-424. K Level of miR-424 in recipient RWPE-1 cells supplemented with EVs from
control (EVs-LNA CTRL) or LNA-transfected (EVs-LNA 424) donor cells. L Tumor-sphere formation by RWPE-1 recipient cells supplemented with EVs-
LNA CTRL or EVs-LNA 424. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.005 by two-tailed Student’s t-test.
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compared to cells treated with WT prostate-derived EVs. To
support the role of miR-424 in this process, we transfected the
LNA antagonist of miR-424/miR-322 in RWPE-1 cells receiving
EVs from ERG/PTEN (EVs-ERG/PTEN) and WT (EVs-WT)
mice (Fig. 5M). The LNA anti-miRNA significantly reduced the
level of miR-322 in recipient cells (Fig. 5N) and reversed the effect
of EVs-ERG/PTEN on tumor-sphere formation (Fig. 5O).
To support the association between aggressive phenotypes and
miR-424 secretion in prostate cancer, we examined two PDX
models (Fig. 6A). Both PDXs have been extensively character-
ized19 and represent valid models of mCSPC (LuCaP #35) and
mCRPC with neuroendocrine features (LuCaP #145.2), respec-
tively (Supplementary Fig. 6A, B). We found that LuCaP #145.2
xenografts had higher level of miR-424 compared to LuCaP #35
tumors (Fig. 6B). Consistently, EVs released by LuCaP #145.2 had
higher content of miR-424 (Fig. 6C). Moreover, when LuCaP
#145.2-derived EVs were supplemented to recipient RWPE-1
cells, we observed enhanced tumor-sphere formation compared
to LuCaP #35-derived EVs (Fig. 6D).
To demonstrate the contribution of miR-424, we ablated miR-
424 in EVs receiving RWPE-1 cells using anti-miR-424 LNA
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miR-424 in recipient cells (Fig. 6F) and accordingly prevented
any increase in tumor-sphere formation promoted by the PDX-
derived EVs (Fig. 6G). Collectively, these findings supported the
oncogenic role of miR-424 in prostate cancer. Furthermore, our
data linked secretion and transfer of miR-424 through EVs to
aggressive tumor phenotypes, suggesting a role of this process in
disease progression to metastatic and hormone-refractory
prostate cancer. In keeping with this hypothesis, we found that
human CRPCs exhibited enhanced transcriptional activation or
repression of genes known to be associated with miR-424
upregulation in primary prostate tumors14 (Supplementary
Fig. 7A, B). Furthermore, these miR-424-associated gene
Fig. 5 Release of miR-424 containing EVs from human tumor xenografts and genetic mouse models. A Assessment of EVs release from human tumor
xenografts. B Growth of subcutaneous tumor xenografts of parental (CTRL) and miR-424-expressing LNCaP (424) cells in NSG mice. n= 4/group. C miR-
424 level in explants of CTRL and 424 tumor xenografts. D miR-424 level in EVs isolated from xenografts (n= 2/group) of parental (EVs-CTRL) and miR-
424-expressing LNCaP (EVs-424) cells. E Tumor-sphere forming assay with RWPE-1-recipient cells incubated with EVs-CTRL and EVs-424 xenograft-
derived EVs. F Cell migration by Boyden chamber assay with RWPE-1 cells incubated with PKH26-labeled EVs-CTRL and EVs-424 from tumor xenografts.
Left, representative phase-contrast and fluorescence microscopy images of RWPE-1 cells. G Schematic plan to evaluate EVs release from transgenic mouse
models and functional characterization. H miR-322 levels in prostatic tissue from wild type (WT) and ERG/PTEN transgenic mice. n= 3/group. I miR-322
content in EVs isolated from prostatic tissue from WT and ERG/PTEN mice. n= 3/group. J Confocal images of RWPE-1 cells incubated for 48 h with EVs
derived from WT (EVs-WT) and ERG/PTEN (EVs-ERG/PTEN) murine prostates. EVs were labeled with PKH26 (red) and supplemented to recipient cells.
EVs (red). Nuclei are stained with Hoechst (blue). K miR-322 level in recipient RWPE-1 cells incubated with EVs-WT or EVs-ERG/PTEN. L Tumor-sphere
assay with RWPE-1 cells supplemented with EVs-WT or EVs-ERG/PTEN.M Schematic of the experimental plan to block miR-424 in recipient cells. N Level
of miR-322 evaluated in recipient cells supplemented with EVs from the indicated GEM source, following blockade of miR-424/322 using LNA-CTRL and
LNA-424. O SFE in RWPE-1 recipient cells transfected with LNA-CTRL and LNA-424 and subsequent supplementation with EVs from the indicated GEM

























































































































Fig. 6 EVs secretion of miR-424 is enhanced in aggressive prostate PDX and promote stemness in prostate epithelial cells. A Schematic plan to
evaluate EVs release from LuCaP/PDX models and functional characterization. B miR-424 level in explants of LuCaP #145.2 (mCRPC) and LuCaP#35
(mCSPC) tumor xenografts (n= 2/group). C Level of miR-424 evaluated in EVs derived from indicated PDX. D Tumor-sphere forming assay with RWPE-1
recipient cells incubated with mCRPC and mCSPC xenografts-derived EVs. E Schematic of the experimental plan to block miR-424 in recipient cells. F Level
of miR-424 evaluated in recipient cells supplemented with EVs from the indicated PDX sources, following blockade of miR-424 using LNA-CTRL and LNA-
424. G SFE in RWPE-1 recipient cells transfected with LNA-CTRL and LNA-424 and subsequent supplementation with EVs from the indicated PDX sources.
*p≤ 0.05, **p≤ 0.01.
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signatures distinguished clearly CRPCs from primary tumors in
unsupervised clustering (Supplementary Fig. 7A, B) and principal
component analysis (Supplementary Fig. 7C, D).
miR-424-loaded circulating EVs are oncogenically active in
mouse models and human patients. Our data suggested that
small EVs or exosomes released by tumors could educate low
tumorigenic cells to acquire stem-like and tumorigenic traits both
locally and at distal metastatic sites. To test the latter point, we
evaluated whether miR-424-loaded EVs given systemically by tail
vein injection could circulate in blood and reach the tumor sites
to release their cargo (Fig. 7A). Mice with subcutaneous implants
of RWPE-1 cells (≥100 mm3) received injections of control (EVs-
CTRL) and miR-424 loaded (EVs-424) EVs derived from LNCaP
cells. Using DiD-labeling and in vivo imaging, we detected
fluorescently labeled EVs in the tumor area at 24 h post-injection
(Fig. 7B), indicating that both EVs preparations reached the
tumors. Importantly, supplementation of EVs-424 enhanced
tumor growth compared to EVs-CTRL (Fig. 7C) and reproduced
the phenotypic changes previously associated with miR-424
upregulation14. Consistently, the level of miR-424 was sig-
nificantly higher in mice receiving EVs-424 compared to EVs-
CTRL (Fig. 7D). The level of COP1, a miR-424 target14, was
reduced whereas total and phosphorylated STAT3 and c-JUN
were increased in EVs-424-treated mice (Fig. 7E). We further
confirmed efficient uptake of miR-424 in implanted RWPE-1
xenografts in an independent experiment, in which mice were
sacrificed 5 days after receiving injections of EVs-CTRL and EVs-
424 and miR-424 quantified in RNA from xenografts by RT-
qPCR (Supplementary Fig. 8A, B). These results demonstrated
that miR-424-containing EVs could travel through the blood
circulation and activated the oncogenic cascade associated with
miR-424 in recipient cells at distal sites.
Next, to verify the oncogenic impact of human circulating EVs
and their ability to educate low tumorigenic cells to acquire stem-
like features, we supplemented RWPE-1 cells with EVs isolated
from plasma (n= 17) of patients with BPH, primary and
metastatic prostate tumors and performed in vitro tumor-
sphere assays (Fig. 7F). Using confocal microscopy, we detected
similar intake of fluorescently labeled EVs independently of their
sources (Fig. 7G). Notably, EVs from mCSPC and mCRPC
patients enhanced tumor-sphere formation significantly more
than those from patients with BPH and primary tumors (Fig. 7H).
Furthermore, high miR-424 content in EVs was significantly
associated with increased induction of tumor-sphere formation
across all samples (Fig. 7I). These data, therefore, were consistent
with the findings in transgenic mice and PDXs described above.
Thus, circulating plasma EVs with high miR-424 content could
reprogram low tumorigenic cells to acquire stem-like potential
and tumorigenic capacity promoting prostate cancer progression.
Discussion
Given their prevalence and stability in biological fluids, miRNAs
can function as efficient inter-cellular signaling molecules acting
in autocrine, paracrine, or endocrine manner6,8,20,14. In this
study, we show for the first time that patients with advanced
prostate cancer release fully functional circulating EVs containing
miR-424, which facilitate the acquisition of stem-like traits by low
tumorigenic cells and thus contribute to disease propagation and
progression. We provide several lines of evidence for the release
of miR-424 into small EVs and its efficient intake by recipient
cells. Using various experimental models, from cell cultures to
PDXs and genetic mouse models, we show that EVs-mediated
transfer of miR-424 propagates the oncogenic signal promoting
stem-like features like in vitro tumor-sphere capability and
in vivo tumor growth. Furthermore, mimicking the action of
circulating EVs in cancer patients, we demonstrate that miR-424-
loaded EVs injected intravenously transfer efficiently their cargo
to subcutaneously implanted recipient cells and promote growth
of the xenografts in mice. Interestingly, in line with a relation
between miR-424 and tumor aggressiveness, we found increased
expression and EVs-mediated release of miR-424 in LNCaPabl
cells, ERG/PTEN mice and PDX LuCaP #145.2, models of
hormone-refractory or invasive adenocarcinomas. Consistently,
miR-424-loaded EVs were preferentially detected in plasma of
patients with metastatic tumors with low or undetectable levels in
primary tumors and BPH. Moreover, patient-derived miR-424-
positive EVs were fully functional and their ability to promote
stemness, a feature associated with increased in vivo tumorigenic
and metastatic capability, was directly related with the clinically
advanced stage and content of miR-424. Future studies in larger
cohorts of patients at various stages of the disease will determine
the validity of miR-424-loaded EVs as biomarker for the man-
agement of prostate cancer and investigate their relation with
other molecular, biological, and clinical features in prostate
tumors. Taken together, our findings indicate that release of miR-
424 in EVs is a property associated with advanced and aggressive
prostate tumors and can facilitate disease recurrence and pro-
gression by allowing rapid transfer of oncogenic signals among
phenotypically heterogeneous tumor cell subpopulations. As
miR-424-loaded EVs can be easily detected in the patient plasma,
their measurement could be used as a minimally invasive test to
identify patients at risk of progressive and metastatic disease.
Furthermore, we show that a miR-424 antagonist is effective in
limiting the release of miR-424 in EVs and the functional con-
sequences in recipient cells, suggesting that this horizontal
pathway of inter-cellular transfer of oncogenic signals may offer
novel targets for therapeutic intervention and drug discovery.
Methods
Human samples. Blood (3–6 mL) was collected from patients with BPH (n= 6),
primary (n= 25), metastatic castration sensitive (mCSPC) (n= 16), and metastatic
castration-resistant prostate cancer (mCRPC) (n= 17), between 2014 and 2019 at
the Portuguese Oncology Institute of Porto (Porto, Portugal), Groote Schuur,
Eerste Rivier and New Somerset Hospitals (Cape Town, South Africa) and
Oncology Institute of Southern Switzerland (Bellinzona, Switzerland). Samples
were collected prior to any treatment at the time of diagnosis or during routine
follow-up for metastatic patients. Metastatic disease was defined by radiologic
progression, whereas CRPC was defined as previously described21.
Plasma collection and processing storage. Plasma was separated by cen-
trifugation (2880 × g, 10 min, 4 °C) from peripheral blood collected in EDTA tubes.
Samples were stored at −80 °C at the Institutions biobanks. Ethical approval for the
study was obtained by the ethical committees of the individual collaborating
Institutions: Comissão de Ética para a Saúde (CES-IPOFG-EPE 205/2013, IPO
Porto), Human Research Ethics Committee (HREC454/2012, University of Cape
Town), and Ethical Committee of Canton Ticino (CE TI 3269 Project-ID
2017–01631, IOSI). Clinical and pathological data (Supplementary Data 1) were
collected in an anonymized database.
Isolation of small EVs from human plasma. EVs were isolated from 1.5 to 2 mL
of patient-derived plasma samples using the Total Exosome Isolation Kit (Catalog
Number: 4484450, Invitrogen) according to the protocol. Plasma was centrifuged
(2000 × g, 20 min, RT) to remove cells and debris. Supernatant was transferred to
clean tube and centrifuged again (10,000 × g, 20 min, RT) to remove further debris.
Pellets were resuspended with 100 µL of PBS and stored at −80 °C until use.
Aliquots of intact EVs were used for protein quantification using bicinchoninic
acid assay (BCA). Isolated EVs were stored at −20 °C until use. For miR-424
evaluation isolated EVs were resuspended in 100 µL of PBS and used for Directzol
RNA extraction (see “RNA extraction, RT-qPCR, and miRNAs expression
analysis”).
EVs isolation from cell medium. Conditioned medium (CM) (3–5 mL) was col-
lected from cells incubated for 48 h and maintained in their standard medium with
EV-depleted FBS. EVs were isolated using miRCURY Exosome isolation kit (Cells,
Urine and CSF, EXIQON, cat. #300102). CM was centrifuged (3000 × g, 10 min,
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RT) to remove cells and debris. We standardized the EVs collection and quanti-
fication by using the following steps: 3–5 × 106 donor cells were seeded in 3–5 mL
in a T25 flask and after 48 h the EVs were isolated using the miRCURY Exosome
isolation kit. After resuspending the intact EVs pellets in 100 µL of PBS, an aliquot
of 20 µL was used for lysis in RIPA buffer 2× with protease inhibitor cocktail
(Roche) and phosphatase inhibitor cocktail (PhosStop; Roche); an aliquot of 20 µL
was used for BCA assay for protein quantification. To isolate larger amounts of
EVs, we used the differential ultracentrifugation (DUC) approach22. Specifically,
cells were cultured in EV-depleted medium at the concentration of 24 × 106 cells/
flask. After 48 h, 30 mL of conditioned medium was centrifuged (300 × g, 10 min, 4
°C). The supernatant was recovered and centrifuged (2000 × g, 10 min, 4 °C). The
recovered supernatant was centrifuged (10,000 × g, 30 min, 4 °C). The supernatant
was ultracentrifuged by using Beckman LE-80K (100,000 × g, 2 h, 4 °C) using a









































































































Fig. 7 Circulating miR-424-loaded EVs are oncogenically active in mouse models and human patients. A Schematic plan for in vivo assessment of EVs
functionality. B In vivo imaging of distribution of DiD-labeled EVs from control (EVs-CTRL) and miR-424 expressing (EVs-424) donor cells 24 h after
intravenous injection to NSG mice with RWPE-1 xenografts. C Growth of RWPE-1 xenografts following single tail vein injection of EVs-CTRL and EVs-424
(n= 4/group). D miR-424 level in RWPE-1 xenografts in mice injected with EVs-CTRL and EVs-424. E Assessment of protein markers by IHC in RWPE-1
xenografts from mice injected with EVs-CTRL and EVs-424. Right, IHC scores for each protein markers. F Functional assessment of patient-derived EVs in
recipient RWPE-1 cells. G Confocal microscopy images of RWPE-1 cells supplemented with patient-derived EVs stained with PKH26 (red). H Tumor-sphere
forming assay of RWPE-1 cells supplemented with EVs derived from the indicated patient groups. Bottom, representative images of tumor-spheres. I
Tumor-sphere forming efficiency of recipient cells as in H shown in relation to miR-424 status after supplementation of patient-derived EVs. *p≤ 0.05,
**p≤ 0.01 by two-tailed Student’s t-test. Following on reports that miR-424 expression promotes oncogenesis, Domenico Albino et al. find that
extracellular vesicles (EVs) in the plasma of prostate cancer patients secrete miR-424. Using cell-based and animal models, they demonstrate that EV-
mediated release of miR-424 can transfer oncogenic signals across cells to promote recurrence and metastatic progression.
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isolated EVs were compatible with the isolation of EVs, according to the minimal
information for studies of extracellular vesicles (MISEV 2018) of the International
Society of EVs15.
RNA extraction, RT-qPCR, and miRNAs expression analysis. Total RNA
extraction was performed using Trizol® (Invitrogen, cat. #TR118) and subsequently
by Direct-zol RNA Miniprep kit (Zymo Research, cat. #R2052) that allows the
recovery of small RNAs. The RNA quality was verified by the spectrophotometric
analysis through the Nanodrop instrument (Thermo Fisher Scientific, cat. #ND-
2000). For miRNA expression analysis, 50 ng of purified total RNA was retro-
transcribed using TaqMan® MicroRNA Reverse Transcription Kit (Applied Bio-
system) with specific primers for the miR-424 (TaqMan® MicroRNA Assays ID:
4427975-000604, Applied Biosystem) and the cDNA was subjected to TaqMan
Probe-based real-time PCR (TaqMan® Universal PCR Master Mix, Applied Bio-
system). Relative expression of miR-424-5p was calculated using the 2−ΔΔCT
method. The miR-424 expression was normalized to RNU6B or miR-21 used as
endogenous controls (Control miRNA assay, RNU6B ID: 4427975-001093, miR-21
ID: 4427975-000397, Applied Biosystem). In all the conditions used in our
experiments we observed constantly similar Ct values for both small-nuclear
ribonucleoprotein (RNU6B) and miR-21. Thus, we used (RNU6B) and miR-21 as
endogenous controls for RT-qPCR.
NTA analysis. The size and concentration of EVs were determined by NTA using
a Nanosight NS300 device (Malvern Instruments). Samples were diluted 1:500 in
PBS, whereby particle concentration was within the optimal range of detection (5 ×
107–1 × 109 particles/mL). Settings were kept fixed during all of the acquisitions in
each experiment. For each sample, at least three measurements were taken and
analyzed using the NTA software 3.0 with default settings.
Transmission electron microscopy. For morphological analysis, EVs suspen-
sions (10 μL) were fixed in 50 μL of 2.5% glutaraldehyde and 2% paraf-
ormaldehyde in 0.1 M sodium cacodylate, pH 7.6 for 1 h. Five microliters of the
mix were transferred onto copper 300 Mesh Formvar-carbon-coated electron
microscopy grids (Pacific Grid Tech, www.grid-tech.com). After 20 min, grids
were transferred on drops of 50 μL of 0.1 M sodium cacodylate pH 7.6 with the
sample membrane side facing down. After three washing in 0.1 M sodium
cacodylate, grids were negatively stained with 2% uracyl acetate in water for 10
min and air dried for 5 min. All samples were observed with a Jeol 1010 EX
electron microscope (Jeol, Tokyo). Data were recorded with a MORADA digital
camera system (Olympus, Tokyo).
EVs immunophenotype analysis (MACSPlex). An aliquot of 60 µL of sample
underwent bead-based multiplex EVs capture and analysis by flow cytometry (FC),
using MACSPlex human Exosome Kit (Miltenyi Biotec; Bergisch Gladbach, Ger-
many), according to manufacturer’s instructions. Briefly, samples were diluted to a
final volume of 120 µL with MACSPlex buffer (MPB) and incubated overnight
(14–16 h) on an orbital shaker (800 rpm, 10 °C, protected from light) with
MACSPlex Exosome Capture Beads, containing 37 antibody-coated bead subsets.
MPB was used as blank control. After incubation, 1 mL of MPB was added to each
tube and then centrifuged (3000 × g, 10 min, 10 °C) to wash beads. After careful
aspiration of 1 mL supernatant, 15 µL of MACSPlex Exosome Detection Reagent
(5 µL for each allophycocyanin [APC]-conjugated anti-CD9, anti-CD63, and anti-
CD81 detection antibody) were added and incubated for 15 min on an orbital
shaker (450 rpm, 10 °C), protected from light. After additional washing step,
samples were manually mixed and immediately loaded and acquired by MACS-
Quant Analyzer 10 flow cytometer (Miltenyi Biotec; Bergisch Gladbach, Germany).
Median fluorescence intensity (MFI) was evaluated for each capture beads subsets
and corrected by subtracting the respective MFI of blank control and normalized
by the mean MFI of CD9, CD63, and CD81. Multiplex platform analysis and gating
strategy were previously described23,24.
Cell cultures. LNCaP cells were obtained from ATCC and maintained in RPMI-
1640 (Gibco) supplemented with 10% fetal bovine serum and 1% of penicillin.
Immortalized human prostate epithelial cells RWPE-1 were maintained in kera-
tinocyte serum-free growth medium (KSF; Gibco) with specific supplements14.
UGSM cells were obtained from ATCC and maintained as previously described14.
LNCaP/RWPE-1 stably expressing miR-424 (LNCaP/RWPE-1-424) and empty
vector (EV) as control (LNCaP/RWPE-1-EV) were established as previously
described14. LNCAPabl were grown in charcoal-stripped serum (CSS) as previously
described25.
For miRNA inhibition, cells were transiently transfected for 48 h with 40 nM of
a specific LNA antagomiR (Mercury LNA Power Inhibitor; Exiqon) or a scrambled
control (Negative Control A; Exiqon). Transfections were performed using
Lipofectamine 2000 reagent (Invitrogen) as previously described14 and miRNA
evaluated as described above. For EVs isolation from transfected cells, 48 h post-
transfection CM was collected for EVs isolation as described above. For transient
miR-424 overexpression with the miRNA precursor, RWPE-1 cells were
transfected for 72 h with 30 nM of miR-424 precursor (miR-424; AM17100-
PM10306, Ambion) or negative control #1 (Ctr; AM17110, Ambion). After 72 h,
miR-424 was measured by RT-qPCR using TaqMan® MicroRNA Assays as
previously described.
Patient-derived xenografts. LuCaP PDX lines #145.2 and #35 were provided by
the laboratory of Prof. Theurillant and were established from specimens acquired at
either radical prostatectomy or at autopsy, implanted, and maintained by serial
passage in immune-compromised male (NOD.Cg-PrkdcSCID Il2rgtm1Wjl/SzJ
(NSG)) mice19. All animal experiments were carried out according to the protocol
approved by the Swiss Veterinary Authority (TI-42-2018).
EVs labeling, supplementation in vitro, and confocal analysis. For uptake
experiments, EVs were fluorescently labeled by using PKH26 or PKH76 kit from
Sigma (MINI26-MINI76). In brief, 5 µg (protein content based) of intact EVs
were incubated with 0.4 µL of red dye diluted in 200 µL of diluent C for 5 min.
Then, the staining was blocked using 10% EXO-depleted FBS, followed by two
centrifugation steps with RPMI-1640. Labeled EVs were used in uptake
experiments. RWPE-1 and LNCaP recipient cells (3000 cells/well/200 µL) were
seeded in IbiTreat µslide-8well, (IBIDI GmbH, Germany, cat. #80826). After 24
h, labeled EVs were added to recipient cells and incubated at 37 °C for additional
24 h. Before image analysis, Hoechst was added and confocal images were taken.
For SFA, after EVs labeling, the equivalent of 8 µg of total EVs-derived proteins,
were used for in vitro supplementation to recipient cells. After 48 h, recipient
cells were trypsinized and counted by trypan blue and used for in vitro and
in vivo experiments. For the tracing of labeled EVs in tumor-spheres forming
assay, 1 µg of PKH76 (green) or 1 µg of PKH26 (red)-labeled EVs derived from
LNCaP-CTRL and LNCaP miR-424 cells were supplemented to RWPE-1-
recipient cells for 48 h. Then, recipient cells were visualized by optical micro-
scope, imaged and tumor-sphere forming assay was performed. After 11 days
tumor-spheres were scored by counting red, green, and mixed colored spheres.
Images were taken by applying red and/or green filters in phase contrast
microscopy.
Localization of miR-424 in EVs (miRNA protection assay). EVs containing
miR-424 were isolated from RWPE-1 miR424 stable cells and incubated with
RNase If (1 µL, 50,000 units/mL, NEB, Ipswich, MA) for 20 min at 30 °C, or with
the addition of 1% Triton. Following incubation, RNA was extracted using Direct-
zol Miniprep kit as described above.
Inhibition of EVs cargo release. Recipient RWPE-1 cells were seeded at 1 × 106
cells/well in 2 mL of standard medium. After 24 h, cells were treated with Bafilo-
mycin A1 (100 nM, B1793, Sigma) or DMSO for 30 min26. Then, EVs derived from
LNCaPabl (5 µg protein content) were supplemented for 48 h and then tumor-
sphere forming assay was performed as described above.
EVs isolation from tissues in tumor xenografts and genetic mouse models.
EVs from xenograft tumor tissues were isolated as previously described17. Tissue
samples were cut into small pieces and incubated in RPMI medium with EXO-
depleted FBS for 12–24 h. The medium collected and centrifuged (800 × g, 10
min, RT), followed by an additional centrifugation step (20,000 × g, 20 min,
RT) to remove any residual cellular debris. Next, the supernatant was filtered
using 0.2-µm filters and transferred to a 15-mL conical tube. Exosome were
isolated using miRCURY Exosome isolation kit and RNA extracted, as described
above. To isolate EVs from prostatic tissue from WT and ERG/PTEN mice27,
prostates were removed from >25-week-old mice, EVs isolated and RNA
extracted as described above. Murine miR-424 (miR-322) was evaluated by
Thermo Fisher probe (TaqMan® MicroRNA Assays ID: 322001076, Applied
Biosystem).
Tumor-sphere formation, cell migration, and invasion assays. Sphere forming
assay was carried out as previously described14. Cell migration ability was assessed
using scratch/wound-healing (WH) assay as previously described with some
modifications11. Conditioned medium (6 mL), obtained from RWPE-1 cells
transfected for 72 h with Pre-miR-424 or Pre-NEG CTRL, was added to RWPE-1-
recipient cells in T25 flask for additional 72 h. Recipient RWPE-1 cells (300,000/
well) were grown to confluence in six-well plates for 24 h and a scratch was
introduced in the cell monolayer. Pictures of cells were taken at 0, 24, and 48 h
using a Zeiss microscope with a Canon EOS 450D camera (×4 magnification).
Wound width was shown as percentage relative to time 0.
Tumor xenografts establishment and in vivo systemic administration of EVs.
NSG mice (4–6 weeks old, Jackson Laboratories) were used for in vivo experi-
ments. RWPE-1 cells (2 × 106) along with UGSM2 cells (2 × 105) in a volume of
200 µL (1:1 volume) of RPMI and Matrigel Matrix (BD Biosciences, 354234, low
density) were injected subcutaneously in mice (n= 4/group).Tumor growth was
monitored every 2 days with a caliper and final tumor weight was measured. For
in vivo systemic administration, EVs were prepared from control (EVs-CTRL)
and miR-424 expressing (EVs-424) donor cells using DUC. To examine in vivo
distribution, EVs were labeled with DiD (Biotium, USA, #60014) for 30 min
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(DiD final concentration 5 mM). After two rounds of centrifugation at
100,000 × g for 3 h, EVs were suspended in PBS. EVs (10 µg protein content/
mouse in 100 µL of PBS) were injected intravenously in tumor-bearing mice.
Total RNA was isolated from xenograft tissues using Tryzol. miR-424 levels were
determined by RT-qPCR as described above. All animal experiments were
conducted with approval of the Swiss Cantonal Authority (CCEA) and in
accordance with national guidelines.
Immunoblotting. Cell lysates were prepared as previously described14 using the
following Ab, CD9 (C-4, sc-13118, Santa Cruz Technology) CD81 (EPR4244,
ab109201, Abcam), GRP94 (cat. #2104, Cell signalling technology), β-actin
(ab8226, Abcam), Calnexin (AF18, cs-23954, Santa Cruz Technology), GAPDH
(cat. #0411, sc-47724, Santa Cruz Biotechnology).
Immunohistochemistry (IHC). IHC was performed as previously described14
using the following Ab: anti-STAT3 (124H6; Cell Signaling; catalog 9139); anti-p-
STAT3 Tyr705 (D3A7; Cell Signaling; catalog 9145); anti-COP1 (ab56400,
Abcam); anti-c-Jun (E254, ab32137); anti-EZH2 (D2C9, CST#5246); anti-Ki67
(Lab Vision Corp.; ready-to-use RT-9106-R7). The specificity of all antibodies was
previously confirmed by Western blot analysis. Cell nuclei were counterstained
with hematoxylin solution. Slides were evaluated by at least two investigators in a
blinded manner.
Statistics and reproducibility. In order to assess the differences in miR-424
positive (Ct level < 40) and negative patients (Ct level undefined) among the four
patients groups, the Fisher’s exact test was employed. The differences in Ct for
miR424 were assessed using the Kruskal–Wallis rank sum test and subsequently
the post-hoc Dunn Test for multiple comparisons. The differences in tumor-sphere
forming efficiency according to the EVs source and miR-424 status were assessed
with the Kruskal-Wallis rank sum test and the post-hoc Dunn Test. In all the tests,
the significant threshold was set to 0.05 and the Benjamini–Hochberg correction
method was adopted.
Bioinformatic analysis. Previously identified miR-424-associated gene sig-
natures (including 1806 upregulated genes and 260 downregulated genes14
(Supplementary Data 2)), were investigated in a cohort of primary and
castration-resistant prostate cancer samples. RNA-Seq datasets, including 497
primary prostate cancers from The Cancer Genome Atlas (TCGA, http://gdac.
broadinstitute.org/) and 75 CRPCs (Fred Hutchinson Cancer Research Center)
was used. Sequencing reads were aligned as previously described28. Heat map
plots were generated in R environment. Principal component analysis was
performed using the PCAtools (R package version 2.0.0. https://github.com/
kevinblighe/PCAtools).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data generated and analyzed during the current study are available in Supplementary
Data 3. Any remaining data can be obtained from the corresponding author upon
reasonable request.
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